ClinicalTrials.gg
CompletedNCT03162796Discover-1Updated Feb 3, 2021Results posted

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 95 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
5th of 14
383 · median 173
Started
2017
with 1 other
Phase 3
7 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Read the detailed description

This is a study of guselkumab in participants with active Psoriatic Arthritis (PsA) who had inadequate response to standard therapies. It will evaluate the clinical efficacy of guselkumab in the reduction of signs and symptoms and the safety profile of guselkumab in the treatment of PsA. The study will consists of 4 phases: a screening phase of up to 6 weeks, a blinded treatment phase of approximately 1 year (that is, 52 weeks), including a placebo controlled period from Week 0 to Week 24 and double-blind active treatment period from Week 24 to Week 52, and a safety follow-up phase of 8 weeks after Week 52 (Week 52 to 60) and will be 12 weeks from the last administration of study agent (at Week 48) to the final safety follow-up visit. Efficacy, safety, pharmacokinetic, immunogenicity, and biomarker evaluations will be performed in the study at defined schedule.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Psoriatic Arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by: at least 3 swollen joints and at least 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram per deciLitre (mg/dL) at screening from the central laboratory
  • Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeter (cm) diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis
  • Have active PsA despite previous non-biologic disease-modifying antirheumatic drugs (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy : Non-biologic DMARD therapy is defined as taking a non-biologic DMARD for at least 3 months or evidence of intolerance; Apremilast therapy is defined as taking apremilast at the marketed dose approved in the country where the study is being conducted for at least 4 months or evidence of intolerance; NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of intolerance
  • Participants may have been previously treated with up to 2 anti-TNF (tumor necrosis factor) alpha agents (approximately 30 percent [%] of the overall study population), and must document the reason for discontinuation

Exclusion criteria

Exclusion Criteria:

  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has ever received more than 2 anti-TNFalpha agents
  • Has previously received any biologic treatment (other than anti-TNF alpha agents), including, but not limited to ustekinumab, abatacept, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab, or other investigative biologic treatment
  • Has previously received any systemic (for example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study agent
  • Has received apremilast within 4 weeks prior to the first administration of study agent
  • Has previously received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.

    Drug: Guselkumab

  • Experimental
    Group 2: Guselkumab and Placebo

    Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 3: Placebo Followed by Guselkumab

    Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.

    Also known as: CNTO 1959

  • DrugPlacebo

    Participants will receive matching placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

    ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24

    ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).

    Time frame: Week 24

  3. Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline

    A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 24

  4. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16

    ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform task in that area), and C-reactive protein (CRP).

    Time frame: Week 16

  5. Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

    The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline and Week 24

  6. Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24

    ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Week 24

  7. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Week 16

  8. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline and Week 24

  9. Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI greater than (\>) 0.

    Time frame: Week 24

  10. Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicates improvement of enthesitis.

    Time frame: Baseline and Week 24

  11. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline and Week 24

  12. Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Week 24

  13. Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative change from baseline indicates improvement in dactylitis.

    Time frame: Baseline and Week 24

  14. Percentage of Participants Who Achieved ACR 20 Response by Visit Over Time Through Week 24

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  15. Percentage of Participants Who Achieved ACR 50 Response by Visit Over Time Through Week 24

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  16. Percentage of Participants Who Achieved ACR 70 Response by Visit Over Time Through Week 24

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  17. ACR Components- Swollen Joint Count and Tender Joint Count Through Week 24

    ACR components including swollen joint count (66 joints) and tender joint count (68 joints) were measured.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  18. ACR Components- Patient's Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity Through Week 24

    ACR components included patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment (PGA) of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis).

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  19. ACR Component- C-reactive Protein (CRP) Through Week 24

    ACR component including CRP was measured.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  20. ACR Component- Patient's Assessment of Physical Function as Assessed by HAQ-DI Scale Score at Weeks 4, 8, 12, 16, 20 and 24

    Patient's assessment of physical function was measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI). HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  21. Percent Change From Baseline in ACR Components at Weeks 4, 8, 12, 16, 20 and 24

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  22. Change From Baseline in HAQ-DI Score at Weeks 4, 8, 12, 16, 20 and 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline, Week 4, 8, 12, 16, 20 and 24

  23. Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score by Visit Over Time Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Week 4, 8, 12, 16, 20 and 24

  24. Percentage of Participants Who Achieved a DAS28 (CRP) Response by Visit Over Time Through Week 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: less than or equal to (\<=) 3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  25. Percentage of Participants Who Achieved a DAS28 (CRP) Remission by Visit Over Time Through Week 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.

    Time frame: Week 4, 8, 12, 16, 20 and 24

  26. Change From Baseline in DAS28 (CRP) Score at Weeks 4, 8, 12, 16, 20 and 24

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative change from baseline indicates improvement of arthritis.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  27. Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) by Visit Over Time Through Week 24

    The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) using VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  28. Percentage of Participants Who Achieved Resolution of Enthesitis at Weeks 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

    Time frame: Weeks 4, 8, 16, and 24

  29. Change From Baseline in Enthesitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  30. Percentage of Participants With Resolution of Dactylitis by Visit Over Time Through Week 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Weeks 4, 8, 16 and 24

  31. Change From Baseline in Dactylitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  32. Change From Baseline in the Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 8, 16 and 24

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Baseline, Weeks 8, 16 and 24

  33. Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score at Weeks 16 and 24

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

    Time frame: Baseline, Weeks 16 and 24

  34. Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 4, 8, 12, 16, 20 and 24

    DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10 centimeter \[cm\] VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  35. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 16 and 24

    MDA was considered achieved if at least 5 of the following 7 criteria were met at the analysis visit: tender joint count \<=1; swollen joint count \<=1; psoriasis activity and severity index \<=1; patient's assessment of pain VAS score of \<=15; patient's global assessment of disease activity VAS (arthritis and psoriasis) score of \<=20; HAQ-DI \<=0.5; and tender entheseal points \<=1.

    Time frame: Weeks 16 and Week 24

  36. Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Weeks 8, 16 and 24

  37. Change From Baseline in BASDAI Score at Week 8, 16, and Week 24 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Baseline, Weeks 8, 16, and 24

  38. Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) by Visit Over Time Through Week 24

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high).

    Time frame: Weeks 8, 16 and 24

  39. Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index by Visit Over Time Through Week 24

    GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of the Desirability Function (AMDF), which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity.

    Time frame: Weeks 16 and 24

  40. Percentage of Participants With Low Disease Activity or Remission Based on Disease Activity Index for Psoriatic Arthritis (DAPSA) by Visit Over Time Through Week 24

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  41. Percentage of Participants With Very Low Disease Activity (VLDA) by Visit Over Time Through Week 24

    A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

    Time frame: Weeks 16 and 24

  42. Percentage of Participants Who Achieved PASI 75 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  43. Percentage of Participants Who Achieved PASI 90 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  44. Percentage of Participants Who Achieved PASI 100 Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.

    Time frame: Weeks 16 and 24

  45. Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

    Time frame: Weeks 16 and 24

  46. Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

    Time frame: Weeks 16 and 24

  47. Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved IGA Score of 0 (cleared) at a specific timepoint and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

    Time frame: Weeks 16 and 24

  48. Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

    Time frame: Baseline, Weeks 16 and 24

  49. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 8, 16 and 24

  50. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 8, 16 and 24

  51. Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Week 8, 16 and 24

  52. Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score by Visit Over Time Through Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 8, 16 and 24

  53. Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score Through Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 8, 16 and 24

  54. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline, Weeks 8, 16 and 24

  55. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 8, 16, and 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Weeks 8, 16, and 24

  56. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 8, 16 and 24

    PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 numeric rating scale (NRS). The raw score of each domain is converted into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for the general population in the US (T-Score).

    Time frame: Baseline, Weeks 8, 16 and 24

  57. Change From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline and Week 24

  58. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Week 24

  59. Percentage of Participants Who Achieved an Improvement of >=3 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24

    PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: Weeks 8, 16, and 24

  60. Percentage of Participants Who Achieved an Improvement of >=5 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24

    PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: Weeks 8, 16, and 24

  61. Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  62. Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  63. Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Weeks 24, 28, 36, 44 and 52

  64. Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

    ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  65. Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  66. Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Weeks 24, 28, 36, 44 and 52

  67. Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  68. Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

    Time frame: Weeks 24, 28, 36, 44 and 52

  69. Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52

    DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

    Time frame: Weeks 24, 28, 36, 44 and 52

  70. Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

    Time frame: Week 52

  71. Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52

    The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

    Time frame: Weeks 24, 28, 36, 44 and 52

  72. Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52

    DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

  73. Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

    Time frame: Weeks 24 and 52

  74. Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

    Time frame: Weeks 24 and 52

  75. Change From Baseline in PASI Score at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative changes from baseline indicate improvement of psoriasis.

    Time frame: Baseline, Weeks 24 and 52

  76. Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  77. Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  78. Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

    Time frame: Weeks 24 and 52

  79. Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score at Weeks 24, 36 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 24, 36 and 52

  80. Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 MCS Score at Weeks 24, 36 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

    Time frame: Weeks 24, 36 and 52

  81. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52

    MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

    Time frame: Weeks 24 and 52

  82. Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

    GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

    Time frame: Baseline, Weeks 24 and 52

  83. Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52

    PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

    Time frame: Baseline, Weeks 24 and 52

  84. Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24

    ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  85. Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24

    ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  86. Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24

    ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

    Time frame: Week 52

  87. Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis as Their Primary Arthritic Presentation of PsA

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

    Time frame: Weeks 24 and 52

  88. Percentage of Participants With Resolution of Enthesitis at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

    Time frame: Weeks 24, 36, 44 and 52

  89. Percentage of Participants With Resolution of Dactylitis at Weeks 24, 36, 44 and 52 Among Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

    Time frame: Weeks 24, 36, 44 and 52

  90. Change From Baseline in Enthesitis Score (Based on SPARCC) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the Spondyloarthritis Research Consortium of Canada (SPARCC). The SPARCC developed a measure for enthesitis in general spondyloarthritis which evaluates the presence or absence of pain by applying local pressure to the following entheses: supraspinatus insertion (left and right), medial epicondyle humerus (left and right), lateral epicondyle humerus (left and right), greater trochanter (left and right), quadriceps-to-patella (left and right), patellar-tibia (left and right), achilles tendon insertion (left and right), plantar fascia (left and right). Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites for an overall score range of 0-16. Higher scores indicate more severe enthesitis. Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 24, 36, 44 and 52

  91. Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

    Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

    Time frame: Baseline, Weeks 24, 36, 44 and 52

  92. Change From Baseline in Dactylitis Score at Weeks 24, 36, 44 and 52 Among the Participants With Dactylitis at Baseline

    The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

    Time frame: Baseline, Weeks 24, 36, 44 and 52

  93. Percentage of Participants With an IGA Score of 0 (Cleared) or 1 (Cleared) at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 24 and 52

  94. Change From Baseline in SF-36 Physical Component Summary (PCS) Score at Weeks 24, 36 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24, 36 and 52

  95. Change From Baseline in SF-36 Mental Component Summary (MCS) Score at Weeks 24, 36 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24, 36 and 52

  96. Change From Baseline in Norm Based Scores of SF-36 Scales at Week 24, 36 and 52

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline, Weeks 24, 36 and 52

  97. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 24, 36 and 52

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline, Weeks 24, 36 and 52

  98. Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 24, 36 and 52

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Weeks 24, 36 and 52

  99. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 24, 36 and 52

    PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: Baseline, Weeks 24, 36 and 52

07

Results

Posted Oct 14, 2020

Participant flow

A total of 383 participants were enrolled. Among them, 381 participants received at least one dose of study drug (126 in placebo group, 127 in guselkumab 100 mg q8w group and 128 in guselkumab 100 mg q4w group). One participant was randomized to guselkumab 100 mg q8w but not treated.

Placebo Controlled Period: Week 0 - 24
Participant flow — Placebo Controlled Period: Week 0 - 24
MilestonePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started126127128
Completed114123125
Not completed1243
Withdrew: Other011
Withdrew: Initiated prohibited medication100
Withdrew: Death100
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject301
Withdrew: Lack of efficacy400
Withdrew: Adverse event231
Active Treatment Period: Week 24 - 52
Participant flow — Active Treatment Period: Week 24 - 52
MilestonePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started114123125
Completed107116124
Not completed771
Withdrew: Withdrawal by subject020
Withdrew: Lack of efficacy431
Withdrew: Adverse event320
Safety Follow-up: Week 52 - 60
Participant flow — Safety Follow-up: Week 52 - 60
MilestonePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started107116124
Completed106114123
Not completed121
Withdrew: Withdrawal by subject121

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 2422.252.059.4
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 29.8 · 95% CI 18.6 to 41.1
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 37.1 · 95% CI 26.1 to 48.2
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24-0.0743 (-0.1605 to 0.0119)-0.3225 (-0.4082 to -0.2369)-0.3968 (-0.4825 to -0.3112)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 · Least square (ls) mean difference: -0.2483 · 95% CI -0.3640 to -0.1325
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 · Ls mean difference: -0.3226 · 95% CI -0.4385 to -0.2066
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24

ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 248.729.935.9
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 21.4 · 95% CI 12.1 to 30.7
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 27.2 · 95% CI 17.6 to 36.8
SecondaryPercentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline

A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline15.457.375.3
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 42.0 · 95% CI 28.9 to 55.1
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 60.0 · 95% CI 48.3 to 71.8
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform task in that area), and C-reactive protein (CRP).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 1625.452.060.2
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 26.7 · 95% CI 15.3 to 38.1
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 (Nominal) · Difference in percentage: 34.8 · 95% CI 23.5 to 46.0
SecondaryChange From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24-0.70 (-0.89 to -0.51)-1.43 (-1.61 to -1.24)-1.61 (-1.80 to -1.42)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.73 · 95% CI -0.98 to -0.48
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 (Nominal) · Ls mean difference: -0.91 · 95% CI -1.16 to -0.66
SecondaryPercentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24

ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 245.611.820.3
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.069 · Difference in percentage: 6.4 · 95% CI -0.3 to 13.1
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Difference in percentage: 14.8 · 95% CI 6.9 to 22.7
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 1612.722.826.6
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.036 (Nominal) · Difference in percentage: 10.2 · 95% CI 1.0 to 19.3
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = 0.006 (Nominal) · Difference in percentage: 13.9 · 95% CI 4.4 to 23.4
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 241.96 (0.69 to 3.24)6.10 (4.83 to 7.37)6.87 (5.60 to 8.14)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = < 0.001 · Ls mean difference: 4.14 · 95% CI 2.42 to 5.85
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = < 0.001 · Ls mean difference: 4.91 · 95% CI 3.19 to 6.63
SecondaryPercentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI greater than (\>) 0.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline27.340.347.9
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.094 (Nominal) · Difference in percentage: 13.0 · 95% CI -1.6 to 27.5
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = 0.013 (Nominal) · Difference in percentage: 19.8 · 95% CI 4.9 to 34.6
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicates improvement of enthesitis.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline-1.01 (-1.37 to -0.66)-1.35 (-1.72 to -0.98)-1.75 (-2.13 to -1.38)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = 0.185 (Nominal) · Ls mean difference: -0.33 · 95% CI -0.83 to 0.16
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = 0.004 (Nominal) · Ls mean difference: -0.74 · 95% CI -1.24 to -0.24
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 242.37 (0.93 to 3.81)3.20 (1.78 to 4.63)3.60 (2.17 to 5.02)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = 0.398 (Nominal) · Ls mean difference: 0.83 · 95% CI -1.10 to 2.77
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = 0.214 (Nominal) · Ls mean difference: 1.23 · 95% CI -0.71 to 3.16
SecondaryPercentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline49.165.363.2
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · Cochran-Mantel-Haenszel · p = 0.088 (Nominal) · Difference in percentage: 16.6 · 95% CI -1.5 to 34.8
  • Placebo vs Guselkumab 100 mg q4w · Cochran-Mantel-Haenszel · p = 0.212 (Nominal) · Difference in percentage: 13.4 · 95% CI -6.9 to 33.7
SecondaryChange From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative change from baseline indicates improvement in dactylitis.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline-4.30 (-5.96 to -2.63)-6.11 (-7.81 to -4.41)-5.82 (-7.82 to -3.83)
Statistical analysis
  • Placebo vs Guselkumab 100 mg q8w · ANCOVA · p = 0.121 (Nominal) · Ls mean difference: -1.82 · 95% CI -4.12 to 0.49
  • Placebo vs Guselkumab 100 mg q4w · ANCOVA · p = 0.225 (Nominal) · Ls mean difference: -1.53 · 95% CI -4.00 to 0.95
SecondaryPercentage of Participants Who Achieved ACR 20 Response by Visit Over Time Through Week 24

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 47.915.720.3
Week 818.336.239.1
Week 1227.043.353.1
Week 1625.452.060.2
Week 2030.251.262.5
Week 2422.252.059.4
SecondaryPercentage of Participants Who Achieved ACR 50 Response by Visit Over Time Through Week 24

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 42.41.63.1
Week 87.97.910.9
Week 1210.320.524.2
Week 1612.722.826.6
Week 2013.529.137.5
Week 248.729.935.9
SecondaryPercentage of Participants Who Achieved ACR 70 Response by Visit Over Time Through Week 24

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 400.80
Week 81.63.12.3
Week 124.87.16.3
Week 165.67.97.8
Week 207.111.817.2
Week 245.611.820.3
SecondaryACR Components- Swollen Joint Count and Tender Joint Count Through Week 24

ACR components including swollen joint count (66 joints) and tender joint count (68 joints) were measured.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · joints
ACR Components- Swollen Joint Count and Tender Joint Count Through Week 24
jointsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4: Swollen Joint Count8.0 ± 7.717.7 ± 7.895.7 ± 4.89
Week 8: Swollen Joint Count6.6 ± 5.836.2 ± 9.364.4 ± 5.22
Week 12: Swollen Joint Count6.1 ± 6.414.5 ± 6.633.5 ± 5.60
Week 16: Swollen Joint Count5.9 ± 6.093.8 ± 5.152.7 ± 4.25
Week 20: Swollen Joint Count5.2 ± 5.724.0 ± 6.282.7 ± 4.87
Week 24: Swollen Joint Count4.9 ± 6.143.8 ± 6.532.8 ± 5.27
Week 4: Tender Joint Count17.0 ± 13.8116.3 ± 14.1114.4 ± 11.85
Week 8: Tender Joint Count15.8 ± 13.6813.5 ± 13.8612.2 ± 11.53
Week 12: Tender Joint Count15.1 ± 14.2111.5 ± 13.169.7 ± 11.14
Week 16: Tender Joint Count15.5 ± 13.6110.3 ± 12.069.0 ± 10.29
Week 20: Tender Joint Count13.4 ± 13.029.9 ± 12.537.9 ± 9.54
Week 24: Tender Joint Count13.2 ± 12.099.9 ± 12.828.4 ± 10.47
SecondaryACR Components- Patient's Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity Through Week 24

ACR components included patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment (PGA) of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis).

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · millimeters
ACR Components- Patient's Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity Through Week 24
millimetersPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4: Patient's Assessment of Pain5.74 ± 2.2965.49 ± 2.1595.18 ± 2.224
Week 8: Patient's Assessment of Pain5.06 ± 2.2574.90 ± 2.3104.54 ± 2.397
Week 12: Patient's Assessment of Pain4.96 ± 2.3554.35 ± 2.5034.09 ± 2.346
Week 16: Patient's Assessment of Pain5.01 ± 2.4174.25 ± 2.4713.85 ± 2.462
Week 20: Patient's Assessment of Pain4.98 ± 2.4974.00 ± 2.4813.51 ± 2.409
Week 24: Patient's Assessment of Pain5.09 ± 2.3793.82 ± 2.4703.52 ± 2.502
Week 4: PtGA of Disease Activity5.86 ± 2.2815.80 ± 2.1815.36 ± 2.200
Week 8: PtGA of Disease Activity5.26 ± 2.2714.99 ± 2.3814.82 ± 2.384
Week 12: PtGA of Disease Activity5.13 ± 2.3984.46 ± 2.4594.18 ± 2.441
Week 16: PtGA of Disease Activity5.12 ± 2.3794.59 ± 2.5413.96 ± 2.458
Week 20: PtGA of Disease Activity5.08 ± 2.5964.21 ± 2.6043.57 ± 2.443
Week 24: PtGA of Disease Activity5.19 ± 2.4194.03 ± 2.6033.48 ± 2.412
Week 4: PGA of Disease Activity5.53 ± 1.9864.94 ± 1.9774.72 ± 1.955
Week 8: PGA of Disease Activity4.79 ± 2.1973.88 ± 2.2993.63 ± 2.035
Week 12: PGA of Disease Activity4.31 ± 2.1963.47 ± 1.9923.08 ± 2.031
Week 16: PGA of Disease Activity4.31 ± 2.2963.39 ± 2.2602.73 ± 2.022
Week 20: PGA of Disease Activity3.96 ± 2.3672.90 ± 2.1322.44 ± 1.780
Week 24: PGA of Disease Activity4.07 ± 2.3612.81 ± 2.1692.34 ± 1.889
SecondaryACR Component- C-reactive Protein (CRP) Through Week 24

ACR component including CRP was measured.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · milligrams per deciliter (mg/dL)
ACR Component- C-reactive Protein (CRP) Through Week 24
milligrams per deciliter (mg/dL)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 41.220 ± 1.57531.159 ± 1.76410.785 ± 1.1917
Week 81.184 ± 1.87221.059 ± 1.47360.720 ± 1.2637
Week 121.138 ± 1.58890.936 ± 1.34700.629 ± 0.7882
Week 161.143 ± 1.60050.996 ± 1.52960.592 ± 0.7861
Week 201.105 ± 1.64010.941 ± 1.50670.592 ± 0.8831
Week 241.319 ± 3.00330.894 ± 1.53860.633 ± 1.0522
SecondaryACR Component- Patient's Assessment of Physical Function as Assessed by HAQ-DI Scale Score at Weeks 4, 8, 12, 16, 20 and 24

Patient's assessment of physical function was measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI). HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · units on a scale
ACR Component- Patient's Assessment of Physical Function as Assessed by HAQ-DI Scale Score at Weeks 4, 8, 12, 16, 20 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 41.2188 ± 0.678061.1371 ± 0.597550.9824 ± 0.65278
Week 81.1331 ± 0.669281.0188 ± 0.614630.9150 ± 0.65488
Week 121.1169 ± 0.638130.9831 ± 0.640580.8012 ± 0.63060
Week 161.1035 ± 0.653720.9375 ± 0.658450.7776 ± 0.66011
Week 201.1049 ± 0.678380.8730 ± 0.623470.7619 ± 0.66491
Week 241.1133 ± 0.692790.8770 ± 0.606910.7264 ± 0.63225
SecondaryPercent Change From Baseline in ACR Components at Weeks 4, 8, 12, 16, 20 and 24

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · percent change
Percent Change From Baseline in ACR Components at Weeks 4, 8, 12, 16, 20 and 24
percent changePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4: Swollen Joint Count-22.4 ± 49.78-27.5 ± 42.92-29.3 ± 50.85
Week 8: Swollen Joint Count-29.4 ± 50.57-45.3 ± 66.29-46.5 ± 53.81
Week 12: Swollen Joint Count-38.1 ± 55.69-60.0 ± 48.23-61.1 ± 42.62
Week 16: Swollen Joint Count-36.6 ± 56.25-65.8 ± 40.42-71.3 ± 34.69
Week 20: Swollen Joint Count-44.4 ± 54.01-66.2 ± 38.24-71.0 ± 40.88
Week 24: Swollen Joint Count-49.5 ± 45.66-66.6 ± 47.09-73.3 ± 37.95
Week 4: Tender Joint Count-15.4 ± 36.11-22.2 ± 36.99-17.2 ± 50.26
Week 8: Tender Joint Count-21.4 ± 41.36-35.7 ± 47.45-31.4 ± 47.13
Week 12: Tender Joint Count-24.5 ± 50.74-48.0 ± 40.24-47.9 ± 38.76
Week 16: Tender Joint Count-19.9 ± 50.84-52.6 ± 36.33-49.2 ± 57.97
Week 20: Tender Joint Count-30.8 ± 53.79-55.4 ± 40.17-59.4 ± 35.91
Week 24: Tender Joint Count-29.1 ± 53.54-53.7 ± 45.12-56.0 ± 41.76
Week 4: Patient's Assessment of Pain2.98 ± 38.337-2.41 ± 43.139-9.12 ± 37.068
Week 8: Patient's Assessment of Pain-7.41 ± 42.846-12.18 ± 46.920-19.41 ± 45.862
Week 12: Patient's Assessment of Pain-7.82 ± 49.910-22.74 ± 45.048-27.28 ± 42.305
Week 16: Patient's Assessment of Pain-7.86 ± 47.980-25.45 ± 47.860-29.74 ± 53.817
Week 20: Patient's Assessment of Pain-8.31 ± 54.287-29.36 ± 46.581-38.45 ± 46.235
Week 24: Patient's Assessment of Pain-5.35 ± 53.599-32.65 ± 45.343-38.97 ± 43.873
Week 4: PtGA of Disease Activity0.06 ± 37.022-9.57 ± 30.374-2.82 ± 58.438
Week 8: PtGA of Disease Activity-9.06 ± 43.197-20.08 ± 45.707-14.95 ± 46.672
Week 12: PtGA of Disease Activity-10.00 ± 49.346-28.38 ± 40.863-26.84 ± 48.800
Week 16: PtGA of Disease Activity-8.56 ± 55.279-26.93 ± 42.999-30.16 ± 47.486
Week 20: PtGA of Disease Activity-11.67 ± 54.531-34.61 ± 40.905-38.76 ± 43.118
Week 24: PtGA of Disease Activity-4.91 ± 65.728-37.16 ± 39.760-40.32 ± 42.037
Week 4: PGA of Disease Activity-10.50 ± 30.144-17.83 ± 34.370-22.42 ± 34.627
Week 8: PGA of Disease Activity-20.87 ± 38.908-36.57 ± 34.906-41.05 ± 31.682
Week 12: PGA of Disease Activity-30.47 ± 32.894-40.61 ± 37.367-48.87 ± 35.082
Week 16: PGA of Disease Activity-29.42 ± 36.058-45.04 ± 36.363-55.36 ± 32.848
Week 20: PGA of Disease Activity-36.48 ± 35.490-51.88 ± 34.491-59.57 ± 30.353
Week 24: PGA of Disease Activity-33.95 ± 34.349-53.43 ± 37.305-61.39 ± 31.234
Week 4: HAQ-DI Score4.3521 ± 61.86548-0.4964 ± 54.63888-5.9245 ± 53.44204
Week 8: HAQ-DI Score-3.3329 ± 48.15101-9.1556 ± 65.76295-11.3467 ± 69.07565
Week 12: HAQ-DI Score-2.1600 ± 88.42239-13.1115 ± 69.57297-21.6242 ± 65.32053
Week 16: HAQ-DI Score-3.2447 ± 109.78825-19.5421 ± 55.80512-27.7444 ± 68.28273
Week 20: HAQ-DI Score-10.5259 ± 44.67386-23.6139 ± 65.27566-26.2478 ± 74.38446
Week 24: HAQ-DI Score-7.3745 ± 61.62081-8.7950 ± 148.19861-31.1750 ± 72.70079
Week 4: CRP9.972 ± 66.9599-4.060 ± 76.1801-1.054 ± 102.5692
:Week 8: CRP10.402 ± 83.47665.403 ± 111.688911.791 ± 273.1510
Week 12: CRP9.295 ± 94.9020-2.507 ± 98.4549-7.908 ± 114.4983
Week 16: CRP82.057 ± 734.65777.139 ± 134.66822.759 ± 208.7305
Week 20: CRP5.768 ± 98.6914-11.151 ± 84.9807-14.684 ± 98.0041
Week 24: CRP31.628 ± 239.7722-7.404 ± 101.4807-6.112 ± 148.2088
SecondaryChange From Baseline in HAQ-DI Score at Weeks 4, 8, 12, 16, 20 and 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline, Week 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in HAQ-DI Score at Weeks 4, 8, 12, 16, 20 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 40.0043 (-0.0562 to 0.0647)-0.0571 (-0.1173 to 0.0031)-0.1095 (-0.1695 to -0.0494)
Week 8-0.0781 (-0.1498 to -0.0064)-0.1711 (-0.2423 to -0.0999)-0.1907 (-0.2619 to -0.1194)
Week 12-0.1013 (-0.1783 to -0.0243)-0.2174 (-0.2938 to -0.1410)-0.3209 (-0.3973 to -0.2444)
Week 16-0.1131 (-0.1955 to -0.0307)-0.2620 (-0.3438 to -0.1802)-0.3393 (-0.4211 to -0.2575)
Week 20-0.1079 (-0.1935 to -0.0223)-0.3293 (-0.4143 to -0.2443)-0.3708 (-0.4558 to -0.2858)
Week 24-0.0743 (-0.1605 to -0.0119)-0.3225 (-0.4082 to -0.2369)-0.3968 (-0.4825 to -0.3112)
SecondaryPercentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score by Visit Over Time Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Week 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score by Visit Over Time Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 420.026.830.9
Week 825.540.238.2
Week 1227.345.551.8
Week 1630.946.457.3
Week 2028.250.956.4
Week 2429.150.957.3
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Response by Visit Over Time Through Week 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: less than or equal to (\<=) 3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Response by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 427.033.140.6
Week 835.759.154.7
Week 1241.367.774.2
Week 1644.465.473.4
Week 2046.066.175.0
Week 2444.470.976.6
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Remission by Visit Over Time Through Week 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.

Time frame:
Week 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Remission by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 43.27.97.8
Week 87.911.011.7
Week 129.522.021.9
Week 167.919.725.0
Week 2017.525.236.7
Week 2412.723.635.9
SecondaryChange From Baseline in DAS28 (CRP) Score at Weeks 4, 8, 12, 16, 20 and 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative change from baseline indicates improvement of arthritis.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in DAS28 (CRP) Score at Weeks 4, 8, 12, 16, 20 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4-0.35 (-0.48 to -0.22)-0.53 (-0.67 to -0.40)-0.56 (-0.69 to -0.43)
Week 8-0.55 (-0.71 to -0.39)-0.83 (-0.99 to -0.67)-0.88 (-1.04 to -0.72)
Week 12-0.63 (-0.80 to -0.47)-1.16 (-1.33 to -0.99)-1.23 (-1.39 to -1.06)
Week 16-0.64 (-0.82 to -0.46)-1.19 (-1.37 to -1.01)-1.38 (-1.56 to -1.20)
Week 20-0.80 (-1.00 to -0.60)-1.38 (-1.58 to -1.19)-1.56 (-1.76 to -1.37)
Week 24-0.70 (-0.89 to -0.51)-1.43 (-1.61 to -1.24)-1.61 (-1.80 to -1.42)
SecondaryPercentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) by Visit Over Time Through Week 24

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) using VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 420.629.133.6
Week 832.556.748.4
Week 1241.358.366.4
Week 1636.564.668.0
Week 2041.366.175.8
Week 2431.059.872.7
SecondaryPercentage of Participants Who Achieved Resolution of Enthesitis at Weeks 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame:
Weeks 4, 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Resolution of Enthesitis at Weeks 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 422.118.127.4
Week 823.430.630.1
Week 1637.734.745.2
Week 2427.340.347.9
SecondaryChange From Baseline in Enthesitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Enthesitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Enthesitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4-0.37 (-0.69 to -0.05)-0.45 (-0.78 to -0.11)-0.96 (-1.30 to -0.62)
Week 8-0.65 (-1.00 to -0.31)-0.83 (-1.19 to -0.47)-1.11 (-1.48 to -0.74)
Week 16-0.99 (-1.36 to -0.61)-1.00 (-1.39 to -0.61)-1.51 (-1.90 to -1.11)
Week 24-1.01 (-1.37 to -0.66)-1.35 (-1.72 to -0.98)-1.75 (-2.13 to -1.38)
SecondaryPercentage of Participants With Resolution of Dactylitis by Visit Over Time Through Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Weeks 4, 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis by Visit Over Time Through Week 24 Among the Participants With Dactylitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 441.834.731.6
Week 841.840.844.7
Week 1643.659.257.9
Week 2449.165.363.2
SecondaryChange From Baseline in Dactylitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4-2.77 (-4.24 to -1.30)-2.24 (-3.76 to -0.72)-2.63 (-4.39 to -0.86)
Week 8-2.92 (-4.58 to -1.26)-4.00 (-5.72 to -2.29)-3.92 (-5.90 to -1.93)
Week 16-4.03 (-5.76 to -2.30)-6.00 (-7.79 to -4.22)-6.29 (-8.36 to -4.22)
Week 24-4.30 (-5.96 to -2.63)-6.11 (-7.81 to -4.41)-5.82 (-7.82 to -3.83)
SecondaryChange From Baseline in the Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 8, 16 and 24

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 8, 16 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8-0.759 (-0.961 to -0.556)-1.315 (-1.518 to -1.113)-1.428 (-1.628 to -1.228)
Week 16-0.980 (-1.221 to -0.739)-1.779 (-2.019 to -1.539)-2.083 (-2.322 to -1.843)
Week 24-0.959 (-1.212 to -0.707)-2.124 (-2.376 to -1.871)-2.407 (-2.657 to -2.156)
SecondaryChange From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score at Weeks 16 and 24

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score at Weeks 16 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-0.918 (-1.176 to -0.659)-2.024 (-2.283 to -1.765)-2.368 (-2.625 to -2.111)
Week 24-0.854 (-1.122 to -0.586)-2.368 (-2.636 to -2.099)-2.735 (-3.001 to -2.468)
SecondaryChange From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 4, 8, 12, 16, 20 and 24

DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10 centimeter \[cm\] VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 4, 8, 12, 16, 20 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 4-4.826 (-6.901 to -2.752)-7.815 (-9.926 to -5.705)-8.574 (-10.636 to -6.511)
Week 8-8.776 (-11.307 to -6.246)-13.601 (-16.118 to -11.084)-13.231 (-15.731 to -10.732)
Week 12-10.135 (-12.670 to -7.599)-18.167 (-20.704 to -15.631)-17.433 (-19.949 to -14.918)
Week 16-9.964 (-12.568 to -7.359)-19.830 (-22.426 to -17.234)-19.389 (-21.977 to -16.802)
Week 20-11.552 (-14.228 to -8.876)-20.570 (-23.248 to -17.891)-21.244 (-23.903 to -18.586)
Week 24-10.749 (-13.396 to -8.102)-21.332 (-23.977 to -18.688)-20.621 (-23.251 to -17.992)
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 16 and 24

MDA was considered achieved if at least 5 of the following 7 criteria were met at the analysis visit: tender joint count \<=1; swollen joint count \<=1; psoriasis activity and severity index \<=1; patient's assessment of pain VAS score of \<=15; patient's global assessment of disease activity VAS (arthritis and psoriasis) score of \<=20; HAQ-DI \<=0.5; and tender entheseal points \<=1.

Time frame:
Weeks 16 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 16 and 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 167.115.718.0
Week 2411.122.830.5
SecondaryPercentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Participants with >=20% Improvement26.158.355.0
Week 16: Participants with >=20% Improvement52.275.065.0
Week 24: Participants with >=20% Improvement26.170.865.0
Week 8: Participants with >=50% Improvement4.325.025.0
Week 16: Participants with >=50% Improvement26.129.235.0
Week 24: Participants with >=50% Improvement13.041.735.0
Week 8: Participants with >=70% Improvement4.34.215.0
Week 16: Participants with >=70% Improvement8.725.015.0
Week 24: Participants with >=70% Improvement8.729.25.0
Week 8: Participants with >=90% Improvement000
Week 16: Participants with >=90% Improvement08.310.0
Week 24: Participants with >=90% Improvement016.70
SecondaryChange From Baseline in BASDAI Score at Week 8, 16, and Week 24 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Baseline, Weeks 8, 16, and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in BASDAI Score at Week 8, 16, and Week 24 Among Participants With Spondylitis and Peripheral Arthritis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8-0.595 (-1.351 to -0.162)-1.577 (-2.296 to -0.859)-1.976 (-2.779 to -1.174)
Week 16-1.604 (-2.483 to -0.725)-2.419 (-3.261 to -1.577)-2.469 (-3.405 to -1.533)
Week 24-0.919 (-1.795 to -0.043)-2.665 (-3.503 to -1.826)-2.074 (-3.006 to -1.142)
SecondaryPercentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) by Visit Over Time Through Week 24

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high).

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 84.010.214.8
Week 168.722.027.3
Week 2411.130.736.7
SecondaryPercentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index by Visit Over Time Through Week 24

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of the Desirability Function (AMDF), which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1610.322.028.9
Week 2411.930.742.2
SecondaryPercentage of Participants With Low Disease Activity or Remission Based on Disease Activity Index for Psoriatic Arthritis (DAPSA) by Visit Over Time Through Week 24

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity or Remission Based on Disease Activity Index for Psoriatic Arthritis (DAPSA) by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Baseline1.62.40.8
Week 410.38.713.3
Week 813.517.325.0
Week 1218.327.637.5
Week 1613.529.936.7
Week 2022.237.846.1
Week 2416.740.949.2
SecondaryPercentage of Participants With Very Low Disease Activity (VLDA) by Visit Over Time Through Week 24

A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Very Low Disease Activity (VLDA) by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 162.43.13.1
Week 241.63.99.4
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1620.563.473.0
Week 2414.175.686.5
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 1610.345.152.8
Week 2411.550.062.9
SecondaryPercentage of Participants Who Achieved PASI 100 Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 100 Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 167.723.232.6
Week 246.425.644.9
SecondaryPercentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 166.435.448.3
Week 246.440.252.8
SecondaryPercentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 169.048.855.1
Week 245.150.062.9
SecondaryPercentage of Participants With an IGA Score of 0 (Cleared) at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved IGA Score of 0 (cleared) at a specific timepoint and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Time frame:
Weeks 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 169.032.940.4
Week 247.737.853.9
SecondaryChange From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

Time frame:
Baseline, Weeks 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 16-2.910 (-4.207 to -1.612)-9.631 (-10.881 to -8.381)-10.096 (-11.318 to -8.874)
Week 24-2.317 (-3.709 to -0.926)-9.974 (-11.323 to -8.624)-10.915 (-12.224 to -9.605)
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) at Weeks 8, 16 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 82.15 (1.06 to 3.23)2.87 (1.80 to 3.95)4.46 (3.39 to 5.54)
Week 162.50 (1.31 to 3.69)5.26 (4.08 to 6.43)6.72 (5.54 to 7.89)
Week 241.96 (0.69 to 3.24)6.10 (4.83 to 7.37)6.87 (5.60 to 8.14)
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Weeks 8, 16 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 81.99 (0.73 to 3.24)2.72 (1.47 to 3.97)2.46 (1.22 to 3.71)
Week 162.25 (0.87 to 3.63)2.61 (1.25 to 3.98)3.04 (1.68 to 4.41)
Week 242.37 (0.93 to 3.81)3.20 (1.78 to 4.63)3.60 (2.17 to 5.02)
SecondaryChange From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Week 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Physical Function Score1.362 (0.201 to 2.524)2.616 (1.456 to 3.777)4.082 (2.927 to 5.237)
Week 16: Physical Function Score1.901 (0.603 to 3.199)5.143 (3.851 to 6.434)6.190 (4.902 to 7.478)
Week 24: Physical Function Score1.636 (0.249 to 3.023)5.776 (4.394 to 7.158)6.952 (5.571 to 8.333)
Week 8: Role-physical Score2.212 (1.104 to 3.321)2.084 (0.978 to 3.190)3.834 (2.730 to 4.938)
Week 16: Role-physical Score2.242 (1.037 to 3.447)4.224 (3.027 to 5.422)5.447 (4.250 to 6.644)
Week 24: Role-physical Score2.319 (1.063 to 3.576)4.878 (3.627 to 6.130)5.442 (4.189 to 6.694)
Week 8: Bodily Pain Score3.081 (1.876 to 4.286)3.886 (2.682 to 5.089)5.140 (3.941 to 6.338)
Week 16: Bodily Pain Score3.125 (1.859 to 4.391)5.059 (3.800 to 6.318)6.778 (5.521 to 8.035)
Week 24: Bodily Pain Score2.854 (1.468 to 4.240)6.840 (5.459 to 8.221)7.490 (6.110 to 8.871)
Week 8: General Health Score1.989 (0.806 to 3.172)3.071 (1.890 to 4.252)3.486 (2.309 to 4.663)
Week 16: General Health Score1.683 (0.492 to 2.874)3.769 (2.585 to 4.953)5.225 (4.042 to 6.408)
Week 24: General Health Score1.690 (0.510 to 2.869)4.349 (3.175 to 5.524)5.174 (3.998 to 6.349)
Week 8: Vitality Score2.312 (1.081 to 3.542)3.917 (2.689 to 5.144)4.614 (3.389 to 5.838)
Week 16: Vitality Score3.084 (1.720 to 4.449)4.777 (3.422 to 6.133)5.589 (4.234 to 6.943)
Week 24: Vitality Score2.311 (0.881 to 3.742)5.596 (4.172 to 7.020)6.426 (5.000 to 7.852)
Week 8: Social Function Score2.025 (0.643 to 3.407)3.287 (1.907 to 4.667)3.798 (2.423 to 5.173)
Week 16: Social Function Score2.455 (1.020 to 3.890)3.531 (2.105 to 4.957)4.817 (3.392 to 6.241)
Week 24: Social Function Score2.582 (1.240 to 3.924)5.426 (4.089 to 6.762)5.227 (3.889 to 6.564)
Week 8: Role-emotional Score1.980 (0.615 to 3.345)2.237 (0.877 to 3.598)1.987 (0.631 to 3.343)
Week 16: Role-emotional Score1.784 (0.316 to 3.253)2.496 (1.040 to 3.953)3.265 (1.810 to 4.720)
Week 24: Role-emotional Score2.201 (0.753 to 3.649)2.415 (0.976 to 3.853)3.531 (2.090 to 4.972)
Week 8: Mental Health Score2.124 (0.901 to 3.348)2.574 (1.358 to 3.790)3.126 (1.914 to 4.339)
Week 16: Mental Health Score2.360 (1.058 to 3.662)3.489 (2.200 to 4.777)3.984 (2.696 to 5.272)
Week 24: Mental Health Score2.062 (0.658 to 3.466)3.818 (2.425 to 5.211)4.356 (2.961 to 5.751)
SecondaryPercentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score by Visit Over Time Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score by Visit Over Time Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 827.033.935.2
Week 1631.032.339.8
Week 2425.437.843.0
SecondaryPercentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score Through Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 831.033.946.1
Week 1629.448.050.0
Week 2428.651.253.9
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 82.356 (1.081 to 3.632)3.643 (2.369 to 4.917)3.576 (2.306 to 4.845)
Week 162.164 (0.782 to 3.547)4.853 (3.478 to 6.228)4.544 (3.171 to 5.918)
Week 242.206 (0.773 to 3.638)5.609 (4.181 to 7.036)5.841 (4.416 to 7.267)
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 8, 16, and 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 8, 16, and 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 835.744.143.8
Week 1634.150.452.3
Week 2434.953.563.3
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 8, 16 and 24

PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 numeric rating scale (NRS). The raw score of each domain is converted into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for the general population in the US (T-Score).

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Least squares mean · T-score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 8, 16 and 24
T-scorePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Anxiety-1.98 (-3.29 to -0.66)-2.19 (-3.50 to -0.88)-1.83 (-3.14 to -0.53)
Week 16: Anxiety-2.30 (-3.63 to -0.97)-3.08 (-4.40 to -1.75)-2.23 (-3.54 to -0.91)
Week 24: Anxiety-1.37 (-2.71 to -0.03)-3.23 (-4.57 to -1.89)-2.92 (-4.25 to -1.59)
Week 8: Depression-0.86 (-2.07 to 0.35)-2.42 (-3.63 to -1.21)-1.54 (-2.74 to -0.34)
Week 16: Depression-0.85 (-2.02 to 0.31)-2.70 (-3.87 to -1.54)-2.69 (-3.85 to -1.54)
Week 24: Depression-0.85 (-2.12 to 0.42)-3.40 (-4.66 to -2.14)-2.67 (-3.92 to -1.41)
Week 8: Fatigue-1.87 (-3.13 to -0.62)-3.25 (-4.50 to -1.99)-2.90 (-4.14 to -1.65)
Week 16: Fatigue-2.29 (-3.57 to -1.02)-4.26 (-5.53 to -2.99)-4.14 (-5.40 to -2.88)
Week 24: Fatigue-1.86 (-3.24 to -0.48)-4.79 (-6.16 to -3.42)-5.08 (-6.45 to -3.71)
Week 8: Pain Interference-2.42 (-3.40 to -1.43)-2.99 (-3.97 to -2.00)-3.32 (-4.30 to -2.33)
Week 16: Pain Interference-2.62 (-3.69 to -1.55)-3.99 (-5.06 to -2.93)-5.02 (-6.08 to -3.96)
Week 24: Pain Interference-2.30 (-3.46 to -1.13)-5.49 (-6.65 to -4.34)-5.69 (-6.85 to -4.53)
Week 8: Physical Function1.34 (0.44 to 2.23)1.31 (0.42 to 2.20)2.37 (1.48 to 3.26)
Week 16: Physical Function1.53 (0.49 to 2.57)3.21 (2.17 to 4.24)4.12 (3.09 to 5.15)
Week 24: Physical Function1.34 (0.25 to 2.43)3.89 (2.81 to 4.98)5.05 (3.96 to 6.13)
Week 8: Sleep Disturbance-1.22 (-2.23 to -0.21)-1.91 (-2.92 to -0.91)-2.09 (-3.09 to -1.09)
Week 16: Sleep Disturbance-1.54 (-2.53 to -0.54)-3.82 (-4.82 to -2.83)-3.09 (-4.08 to -2.10)
Week 24: Sleep Disturbance-1.17 (-2.25 to -0.09)-3.48 (-4.56 to -2.40)-2.46 (-3.53 to -1.38)
Week 8: Satisfaction-Social Role and Activity1.52 (0.39 to 2.64)3.13 (2.01 to 4.25)3.18 (2.06 to 4.29)
Week 16: Satisfaction-Social Role and Activity1.86 (0.65 to 3.08)3.93 (2.72 to 5.14)3.97 (2.76 to 5.17)
Week 24: Satisfaction-Social Role and Activity1.45 (0.22 to 2.69)4.90 (3.66 to 6.13)4.52 (3.29 to 5.75)
Week 8: Pain Intensity-0.74 (-1.06 to -0.41)-1.34 (-1.66 to -1.01)-1.28 (-1.61 to -0.96)
Week 16: Pain Intensity-0.73 (-1.09 to -0.37)-1.63 (-1.98 to -1.27)-2.03 (-2.38 to -1.67)
Week 24: Pain Intensity-0.56 (-0.94 to -0.19)-1.98 (-2.36 to -1.61)-2.32 (-2.69 to -1.94)
SecondaryChange From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Among ACR 20 responders8.571 ± 7.89959.242 ± 10.84736.684 ± 8.0948
Among ACR 20 non-responders0.316 ± 6.81811.984 ± 7.88773.635 ± 6.8170
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Among ACR 20 responders67.968.273.7
Among ACR 20 non-responders25.537.748.1
SecondaryPercentage of Participants Who Achieved an Improvement of >=3 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24

PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement of >=3 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Anxiety41.341.739.1
Week 16: Anxiety-34.942.541.4
Week 24: Anxiety34.945.742.2
Week 8: Depression24.630.734.4
Week 16: Depression25.435.433.6
Week 24: Depression26.239.438.3
Week 8: Fatigue34.139.442.2
Week 16: Fatigue38.949.649.2
Week 24: Fatigue32.548.855.5
Week 8: Pain Interference34.941.743.8
Week 16: Pain Interference39.747.256.3
Week 24: Pain Interference33.354.357.0
Week 8: Physical Function28.630.740.6
Week 16: Physical Function28.644.145.3
Week 24: Physical Function22.248.053.9
Week 8: Sleep Disturbance35.738.639.1
Week 16: Sleep Disturbance36.548.838.3
Week 24: Sleep Disturbance31.048.840.6
Week 8: Satisfaction-Social Role and Activity35.744.949.2
Week 16: Satisfaction-Social Role and Activity37.346.546.1
Week 24: Satisfaction-Social Role and Activity32.552.050.0
Week 8: Pain Intensity15.122.826.6
Week 16: Pain Intensity18.333.142.2
Week 24: Pain Intensity15.137.045.3
SecondaryPercentage of Participants Who Achieved an Improvement of >=5 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24

PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement of >=5 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 8: Anxiety33.337.029.7
Week 16: Anxiety29.434.633.6
Week 24: Anxiety28.641.738.3
Week 8: Depression17.527.626.6
Week 16: Depression19.032.328.9
Week 24: Depression19.836.230.5
Week 8: Fatigue27.829.133.6
Week 16: Fatigue33.340.943.0
Week 24: Fatigue31.045.747.7
Week 8: Pain Interference22.229.935.9
Week 16: Pain Interference29.438.643.8
Week 24: Pain Interference23.846.551.6
Week 8: Physical Function15.118.922.7
Week 16: Physical Function18.326.832.8
Week 24: Physical Function15.936.239.8
Week 8: Sleep Disturbance24.624.427.3
Week 16: Sleep Disturbance24.640.230.5
Week 24: Sleep Disturbance21.437.032.8
Week 8: Satisfaction-Social Role and Activity25.440.238.3
Week 16: Satisfaction-Social Role and Activity30.242.539.8
Week 24: Satisfaction-Social Role and Activity22.245.743.0
Week 8: Pain Intensity5.66.36.3
Week 16: Pain Intensity6.38.714.8
Week 24: Pain Intensity4.018.118.0
SecondaryPercentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2427.254.560.8
Week 2850.068.974.4
Week 3656.970.371.1
Week 4461.773.572.0
Week 5268.367.975.8
SecondaryPercentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 249.630.936.8
Week 2821.442.639.2
Week 3632.747.144.6
Week 4430.851.346.0
Week 5236.543.455.6
SecondaryPercentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 246.112.220.8
Week 289.820.524.8
Week 3618.025.226.4
Week 4416.828.426.4
Week 5219.228.929.8
SecondaryPercent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
percent changePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Swollen Joint Count-48.33 ± 45.987-66.62 ± 47.086-73.23 ± 38.120
Week 28: Swollen Joint Count-59.95 ± 47.826-75.42 ± 33.774-80.93 ± 27.197
Week 36: Swollen Joint Count-70.50 ± 37.359-79.16 ± 35.141-80.19 ± 29.160
Week 44: Swollen Joint Count-72.63 ± 38.625-80.35 ± 34.653-82.46 ± 31.652
Week 52: Swollen Joint Count-78.23 ± 37.345-79.63 ± 36.471-86.73 ± 26.776
Week 24: Tender Joint Count-27.58 ± 53.737-53.73 ± 45.118-56.56 ± 41.774
Week 28: Tender Joint Count-42.99 ± 62.128-64.03 ± 40.678-66.68 ± 31.528
Week 36: Tender Joint Count-57.06 ± 43.351-68.44 ± 39.771-64.67 ± 41.606
Week 44: Tender Joint Count-60.08 ± 42.811-69.23 ± 51.229-71.90 ± 31.422
Week 52: Tender Joint Count-65.65 ± 37.682-72.39 ± 35.102-72.70 ± 37.487
Week 24: Patient's Assessment of Pain-6.05 ± 52.682-32.65 ± 45.343-38.90 ± 43.955
Week 28: Patient's Assessment of Pain-21.93 ± 52.597-38.86 ± 45.149-43.59 ± 39.524
Week 36: Patient's Assessment of Pain-27.61 ± 56.373-42.85 ± 43.952-47.23 ± 41.167
Week 44: Patient's Assessment of Pain-27.98 ± 64.080-45.27 ± 47.794-48.97 ± 36.509
Week 52: Patient's Assessment of Pain-35.64 ± 66.672-42.67 ± 47.250-50.03 ± 50.203
Week 24: PtGA of Disease Activity-7.63 ± 58.147-37.16 ± 39.760-40.27 ± 42.250
Week 28: PtGA of Disease Activity-21.74 ± 57.662-45.35 ± 41.564-37.62 ± 60.121
Week 36: PtGA of Disease Activity-26.51 ± 60.926-46.03 ± 39.547-45.17 ± 39.277
Week 44: PtGA of Disease Activity-21.76 ± 81.481-46.11 ± 40.973-45.84 ± 43.368
Week 52: PtGA of Disease Activity-35.17 ± 56.398-45.84 ± 42.176-47.85 ± 55.429
Week 24: PGA of Disease Activity-33.22 ± 34.014-53.43 ± 37.305-61.59 ± 31.445
Week 28: PGA of Disease Activity-53.88 ± 31.619-57.70 ± 33.724-65.96 ± 29.400
Week 36: PGA of Disease Activity-62.40 ± 29.215-64.51 ± 34.389-68.37 ± 27.206
Week 44: PGA of Disease Activity-64.93 ± 28.895-69.08 ± 30.743-72.65 ± 25.842
Week 52: PGA of Disease Activity-68.67 ± 32.861-68.83 ± 32.776-74.71 ± 25.456
Week 24: HAQ-DI score-7.65 ± 62.206-8.80 ± 148.199-31.18 ± 72.701
Week 28: HAQ-DI score-15.62 ± 51.720-29.10 ± 60.044-33.41 ± 72.942
Week 36: HAQ-DI score-15.37 ± 53.391-29.43 ± 73.712-32.74 ± 86.404
Week 44: HAQ-DI score-29.61 ± 45.603-34.54 ± 73.685-35.91 ± 80.885
Week 52: HAQ-DI score-28.42 ± 45.473-31.09 ± 60.232-46.13 ± 56.354
Week 24: CRP-13.58 ± 150.494-7.83 ± 101.789-6.48 ± 149.288
Week 28: CRP-8.67 ± 122.851-5.58 ± 99.590-10.30 ± 97.703
Week 36: CRP-17.33 ± 102.168-31.55 ± 50.560-14.65 ± 113.746
Week 44: CRP-29.10 ± 70.460-17.81 ± 76.247-4.39 ± 190.368
Week 52: CRP-1.68 ± 167.086-19.28 ± 69.875-15.76 ± 129.101
SecondaryChange From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-0.1217 ± 0.52442-0.3374 ± 0.56967-0.3740 ± 0.45914
Week 28-0.2241 ± 0.50876-0.4004 ± 0.52303-0.3850 ± 0.46381
Week 36-0.2602 ± 0.51278-0.4396 ± 0.54426-0.4132 ± 0.47155
Week 44-0.3634 ± 0.53486-0.4672 ± 0.57140-0.4180 ± 0.51394
Week 52-0.3642 ± 0.51084-0.4364 ± 0.56400-0.4970 ± 0.47990
SecondaryPercentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2436.053.257.8
Week 2840.261.561.5
Week 3641.760.461.9
Week 4450.058.762.4
Week 5254.357.468.5
SecondaryChange From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-0.84 ± 1.043-1.49 ± 1.140-1.57 ± 1.045
Week 28-1.33 ± 1.121-1.71 ± 1.126-1.67 ± 1.020
Week 36-1.60 ± 1.123-1.96 ± 1.145-1.78 ± 1.054
Week 44-1.69 ± 1.224-1.96 ± 1.226-1.92 ± 1.116
Week 52-1.84 ± 1.087-2.03 ± 1.250-1.99 ± 1.062
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2451.874.678.4
Week 2873.683.383.9
Week 3676.489.086.8
Week 4480.086.889.5
Week 5286.488.487.8
SecondaryPercentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2414.924.636.8
Week 2826.437.538.7
Week 3639.140.740.5
Week 4438.145.651.6
Week 5237.943.856.1
SecondaryPercentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 2484.987.3
SecondaryPercentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame:
Weeks 24, 28, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2437.263.174.4
Week 2864.978.782.3
Week 3668.880.580.0
Week 4473.881.980.0
Week 5273.883.883.9
SecondaryChange From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame:
Baseline, Weeks 24, 28, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-12.962 ± 17.9137-23.373 ± 20.2784-20.530 ± 13.2678
Week 28-18.632 ± 19.4997-26.790 ± 19.3655-22.766 ± 12.8366
Week 36-22.360 ± 18.8976-30.070 ± 21.0899-24.067 ± 14.0976
Week 44-23.602 ± 19.9198-30.312 ± 22.5854-26.010 ± 15.3230
Week 52-26.058 ± 18.6507-30.906 ± 23.0188-26.562 ± 15.1985
SecondaryPercentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 248.850.663.6
Week 5269.270.779.5
SecondaryPercentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2410.340.753.4
Week 5264.658.773.9
SecondaryChange From Baseline in PASI Score at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative changes from baseline indicate improvement of psoriasis.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in PASI Score at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-3.046 ± 9.3053-9.968 ± 10.0178-11.614 ± 10.3771
Week 52-10.565 ± 8.8792-10.431 ± 11.0277-11.988 ± 10.3067
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2420.676.587.5
Week 5284.880.094.3
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2413.250.663.6
Week 5272.766.776.1
SecondaryPercentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 247.425.945.5
Week 5262.148.064.8
SecondaryPercentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score at Weeks 24, 36 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 24, 36 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score at Weeks 24, 36 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2435.153.755.6
Week 3644.953.855.0
Week 5252.953.562.9
SecondaryPercentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 MCS Score at Weeks 24, 36 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame:
Weeks 24, 36 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 MCS Score at Weeks 24, 36 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2429.839.044.4
Week 3639.339.549.2
Week 5237.546.547.6
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52

MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2412.323.631.2
Week 5231.133.940.3
SecondaryChange From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-0.998 ± 1.4808-2.493 ± 1.5195-2.751 ± 1.5060
Week 52-2.829 ± 1.5773-3.112 ± 1.7479-3.364 ± 1.4638
SecondaryChange From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.140 ± 1.4036-2.246 ± 1.4978-2.413 ± 1.3906
Week 52-2.748 ± 1.4706-2.897 ± 1.6788-3.026 ± 1.4446
SecondaryPercentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 2488.590.8
SecondaryPercentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 2483.891.3
SecondaryPercentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24
percentage of participantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 2480.084.6
SecondaryPercentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis as Their Primary Arthritic Presentation of PsA

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis as Their Primary Arthritic Presentation of PsA
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Participants with >=20% Improvement38.170.865.0
Week 52: Participants with >=20% Improvement66.772.785.0
Week 24: Participants with >=50% Improvement19.041.735.0
Week 52: Participants with >=50% Improvement52.459.150.0
Week 24: Participants with >=70% Improvement14.329.25.0
Week 52: Participants with >=70% Improvement28.640.920.0
Week 24: Participants with >=90% Improvement016.70
Week 52: Participants with >=90% Improvement9.513.615.0
SecondaryPercentage of Participants With Resolution of Enthesitis at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame:
Weeks 24, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2431.040.849.3
Week 3649.352.958.0
Week 4458.246.471.8
Week 5269.856.362.9
SecondaryPercentage of Participants With Resolution of Dactylitis at Weeks 24, 36, 44 and 52 Among Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame:
Weeks 24, 36, 44 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Weeks 24, 36, 44 and 52 Among Participants With Dactylitis at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2461.767.364.9
Week 3679.567.482.9
Week 4484.876.183.8
Week 5281.479.578.4
SecondaryChange From Baseline in Enthesitis Score (Based on SPARCC) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the Spondyloarthritis Research Consortium of Canada (SPARCC). The SPARCC developed a measure for enthesitis in general spondyloarthritis which evaluates the presence or absence of pain by applying local pressure to the following entheses: supraspinatus insertion (left and right), medial epicondyle humerus (left and right), lateral epicondyle humerus (left and right), greater trochanter (left and right), quadriceps-to-patella (left and right), patellar-tibia (left and right), achilles tendon insertion (left and right), plantar fascia (left and right). Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites for an overall score range of 0-16. Higher scores indicate more severe enthesitis. Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 24, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Enthesitis Score (Based on SPARCC) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.9 ± 3.55-2.7 ± 3.68-3.0 ± 3.60
Week 36-3.1 ± 3.61-3.4 ± 3.90-3.6 ± 3.52
Week 44-3.6 ± 3.67-3.6 ± 3.82-4.1 ± 3.55
Week 52-3.9 ± 3.57-4.1 ± 4.04-4.0 ± 3.51
SecondaryChange From Baseline in Enthesitis Score (Based on LEI) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.

Time frame:
Baseline, Weeks 24, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-1.0 ± 1.68-1.2 ± 1.95-1.8 ± 1.93
Week 36-1.4 ± 1.73-1.3 ± 2.04-2.0 ± 1.68
Week 44-1.6 ± 1.90-1.6 ± 1.70-2.4 ± 1.68
Week 52-1.9 ± 1.65-1.8 ± 1.66-2.0 ± 1.87
SecondaryChange From Baseline in Dactylitis Score at Weeks 24, 36, 44 and 52 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

Time frame:
Baseline, Weeks 24, 36, 44 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Dactylitis Score at Weeks 24, 36, 44 and 52 Among the Participants With Dactylitis at Baseline
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24-4.0 ± 6.08-6.2 ± 10.31-6.6 ± 11.08
Week 36-6.0 ± 7.17-6.4 ± 10.91-7.7 ± 11.58
Week 44-5.3 ± 5.61-7.2 ± 10.57-7.5 ± 11.41
Week 52-5.7 ± 5.86-7.8 ± 10.55-7.6 ± 10.91
SecondaryPercentage of Participants With an IGA Score of 0 (Cleared) or 1 (Cleared) at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 (Cleared) or 1 (Cleared) at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 248.838.354.5
Week 5266.253.367.0
SecondaryChange From Baseline in SF-36 Physical Component Summary (PCS) Score at Weeks 24, 36 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24, 36 and 52
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 Physical Component Summary (PCS) Score at Weeks 24, 36 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 242.700 ± 7.16496.505 ± 7.71376.560 ± 7.7566
Week 365.456 ± 8.03537.439 ± 8.56267.162 ± 7.9890
Week 526.905 ± 7.93767.278 ± 8.06488.517 ± 8.2717
SecondaryChange From Baseline in SF-36 Mental Component Summary (MCS) Score at Weeks 24, 36 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24, 36 and 52
Reported as:
Mean · units on a scale
Change From Baseline in SF-36 Mental Component Summary (MCS) Score at Weeks 24, 36 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 241.827 ± 8.15083.027 ± 10.61573.796 ± 8.7396
Week 363.612 ± 7.23224.300 ± 10.23734.326 ± 9.2709
Week 524.240 ± 8.12005.139 ± 9.17194.931 ± 8.9482
SecondaryChange From Baseline in Norm Based Scores of SF-36 Scales at Week 24, 36 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline, Weeks 24, 36 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Norm Based Scores of SF-36 Scales at Week 24, 36 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Physical Functioning1.914 ± 8.86446.006 ± 7.96086.652 ± 8.4730
Week 36: Physical Functioning5.008 ± 8.64616.900 ± 8.54587.114 ± 8.8941
Week 52: Physical Functioning6.257 ± 8.37537.000 ± 8.09538.720 ± 8.9738
Week 24: Role-physical3.053 ± 7.64605.239 ± 8.28645.215 ± 7.5241
Week 36: Role-physical4.701 ± 8.15726.245 ± 7.83466.250 ± 7.9040
Week 52: Role-physical5.873 ± 8.88476.126 ± 8.10087.063 ± 8.2579
Week 24: Bodily Pain3.388 ± 7.20567.058 ± 8.83157.215 ± 9.1129
Week 36: Bodily Pain6.477 ± 8.63638.487 ± 8.81357.348 ± 9.0965
Week 52: Bodily Pain8.331 ± 8.15858.781 ± 8.56918.958 ± 9.1783
Week 24: General Health1.819 ± 6.94974.361 ± 7.55735.066 ± 7.1334
Week 36: General Health3.742 ± 8.20795.638 ± 8.49195.540 ± 7.4840
Week 52: General Health4.677 ± 7.89445.547 ± 7.87126.442 ± 7.9374
Week 24: Vitality2.684 ± 9.00495.652 ± 9.69436.158 ± 7.8842
Week 36: Vitality6.303 ± 9.03077.065 ± 8.66597.353 ± 8.7656
Week 52: Vitality7.742 ± 8.74767.558 ± 9.16008.218 ± 8.5308
Week 24: Social Function2.419 ± 8.82895.666 ± 9.34494.932 ± 9.5887
Week 36: Social Function4.873 ± 9.14775.899 ± 9.97625.598 ± 10.5240
Week 52: Social Function5.351 ± 8.92646.729 ± 8.48446.428 ± 10.1397
Week 24: Role-emotional1.833 ± 9.08002.265 ± 10.61553.706 ± 9.3529
Week 36: Role-emotional3.580 ± 8.53534.301 ± 10.11273.685 ± 10.5307
Week 52: Role-emotional4.520 ± 8.86584.979 ± 10.29564.830 ± 9.9053
Week 24: Mental Health1.905 ± 8.11964.062 ± 10.06104.873 ± 8.6431
Week 36: Mental Health3.472 ± 7.07615.056 ± 9.79305.559 ± 8.9957
Week 52: Mental Health4.251 ± 8.30595.553 ± 8.42556.223 ± 8.8360
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 24, 36 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline, Weeks 24, 36 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 24, 36 and 52
units on a scalePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 242.605 ± 8.31425.862 ± 10.39415.576 ± 7.7670
Week 365.981 ± 8.38467.252 ± 9.71825.917 ± 8.5123
Week 526.577 ± 9.41057.482 ± 9.63426.911 ± 8.3986
SecondaryPercentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 24, 36 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Weeks 24, 36 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 24, 36 and 52
percentage of participantsPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 2441.255.364.8
Week 3660.758.066.1
Week 5263.561.463.7
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 24, 36 and 52

PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

Time frame:
Baseline, Weeks 24, 36 and 52
Reported as:
Mean · T-score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 24, 36 and 52
T-scorePlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 24: Anxiety Score-1.482 ± 8.3526-3.680 ± 9.8122-3.115 ± 7.9491
Week 36: Anxiety Score-2.410 ± 7.6503-3.929 ± 8.9614-2.961 ± 8.4679
Week 52: Anxiety Score-3.640 ± 8.3601-4.279 ± 9.6488-3.075 ± 8.5784
Week 24: Depression Score-0.601 ± 8.3133-3.963 ± 8.5473-2.706 ± 8.1872
Week 36: Depression Score-0.933 ± 7.1629-3.916 ± 8.6211-2.987 ± 7.8786
Week 52: Depression Score-2.488 ± 7.8259-4.004 ± 7.5271-2.985 ± 8.0519
Week 24: Fatigue Score-2.104 ± 7.5625-4.780 ± 9.7044-4.757 ± 7.7779
Week 36: Fatigue Score-5.533 ± 8.3256-5.857 ± 8.8525-5.693 ± 9.3854
Week 52: Fatigue Score-5.720 ± 9.0165-6.773 ± 8.5608-5.583 ± 8.1099
Week 24: Pain Interference Score-2.811 ± 5.9890-5.810 ± 7.5201-5.423 ± 7.1593
Week 36: Pain Interference Score-5.344 ± 7.2500-6.754 ± 8.0520-5.882 ± 7.5121
Week 52: Pain Interference Score-6.334 ± 6.9940-6.972 ± 8.2440-6.242 ± 7.4767
Week 24: Physical Function Score1.682 ± 5.99094.101 ± 7.13535.030 ± 6.5259
Week 36: Physical Function Score3.093 ± 6.57124.970 ± 7.00125.264 ± 7.0643
Week 52: Physical Function Score4.245 ± 6.13635.033 ± 7.01845.920 ± 6.9852
Week 24: Sleep Disturbance Score-1.497 ± 5.7591-3.750 ± 6.8758-2.549 ± 6.7263
Week 36: Sleep Disturbance Score-2.767 ± 5.7630-3.853 ± 6.5505-4.096 ± 6.8724
Week 52: Sleep Disturbance Score-3.290 ± 5.8368-4.375 ± 6.5738-3.856 ± 6.1181
Week24:Satisfaction-Social Role and Activity Score1.666 ± 7.25725.308 ± 8.58084.235 ± 7.4745
Week36:Satisfaction-Social Role and Activity Score4.120 ± 8.18996.270 ± 8.87984.517 ± 7.9605
Week52:Satisfaction-Social Role and Activity Score4.885 ± 8.74216.607 ± 7.84385.347 ± 8.1806
Week 24: Pain Intensity Score-0.737 ± 2.0911-2.098 ± 2.4104-2.320 ± 2.4449
Week 36: Pain Intensity Score-1.720 ± 2.3424-2.496 ± 2.4212-2.488 ± 2.4018
Week 52: Pain Intensity Score-2.462 ± 2.3480-2.711 ± 2.4844-2.847 ± 2.5377

Adverse events

Collected over Up to Week 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (CP)2/126 (1.6%)5/126 (4%)25/126 (19.8%)
Guselkumab 100 mg q8w (CP)0/127 (0%)4/127 (3.1%)38/127 (29.9%)
Guselkumab 100 mg q4w (CP)0/128 (0%)0/128 (0%)28/128 (21.9%)
Placebo to Guselkumab 100 mg q4w (ACP Through Week 60)0/114 (0%)4/114 (3.5%)25/114 (21.9%)
Guselkumab 100 mg q8w (Through Week 60)0/127 (0%)8/127 (6.3%)48/127 (37.8%)
Guselkumab 100 mg q4w (Through Week 60)0/128 (0%)4/128 (3.1%)41/128 (32%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo (CP)Guselkumab 100 mg q8w (CP)Guselkumab 100 mg q4w (CP)Placebo to Guselkumab 100 mg q4w (ACP Through Week 60)Guselkumab 100 mg q8w (Through Week 60)Guselkumab 100 mg q4w (Through Week 60)
Atrial FibrillationCardiac disorders0/1260/1270/1281/1140/1270/128
PyelonephritisInfections and infestations0/1260/1270/1281/1140/1270/128
UrosepsisInfections and infestations0/1260/1270/1281/1140/1270/128
Head InjuryInjury, poisoning and procedural complications0/1260/1270/1281/1140/1270/128
Cardiac FailureCardiac disorders1/1260/1270/1280/1140/1270/128
PainGeneral disorders1/1260/1270/1280/1140/1270/128
Abscess LimbInfections and infestations1/1260/1270/1280/1140/1270/128
PneumoniaInfections and infestations1/1260/1270/1280/1140/1270/128
Upper Respiratory Tract InfectionInfections and infestations1/1260/1270/1280/1140/1270/128
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/1260/1270/1280/1140/1270/128
Most frequent other events
Most frequent other events
EventPlacebo (CP)Guselkumab 100 mg q8w (CP)Guselkumab 100 mg q4w (CP)Placebo to Guselkumab 100 mg q4w (ACP Through Week 60)Guselkumab 100 mg q8w (Through Week 60)Guselkumab 100 mg q4w (Through Week 60)
NasopharyngitisInfections and infestations8/12616/1277/12813/11421/12714/128
Upper Respiratory Tract InfectionInfections and infestations8/1267/12711/1288/11410/12716/128
Aspartate Aminotransferase IncreasedInvestigations3/1269/1273/1284/11411/1276/128
BronchitisInfections and infestations1/1265/1271/1283/1149/1272/128
Alanine Aminotransferase IncreasedInvestigations3/1268/1275/1284/1149/1279/128
EnthesopathyMusculoskeletal and connective tissue disorders6/1266/1276/1280/1147/1278/128

Baseline characteristics

Full Analysis Set (FAS) 1 included all participants who received at least 1 dose (complete/partial) of study agent according to randomized treatment group regardless of treatment actually received.

Age, Continuous
Age, Continuous(years)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Mean49 ± 11.148.9 ± 11.5247.4 ± 11.5948.4 ± 11.39
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Female655962186
Male616866195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Hispanic or Latino2204
Not Hispanic or Latino122124128374
Unknown or Not Reported2103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
American Indian or Alaska Native0000
Asian1210729
Native Hawaiian or Other Pacific Islander0101
Black or African American0000
White112116121349
More than one race0000
Unknown or Not Reported2002
Region of Enrollment
Region of Enrollment(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
AUSTRALIA58417
CANADA83415
CZECH REPUBLIC54312
GERMANY3101023
HUNGARY34916
MALAYSIA5128
POLAND373634107
RUSSIAN FEDERATION22192364
SOUTH KOREA3104
SPAIN56112
TAIWAN47516
UKRAINE19222970
UNITED STATES76417
08

Study locations

95 sites
  • Rheumatology Associates
    Birmingham, Alabama 35205, United States
  • Arizona Arthritis & Rheumatology Associates PC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Clinical Research Center of Connecticut
    Danbury, Connecticut 06810, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256-4697, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • Arthritis and Osteoporosis Associates
    Freehold, New Jersey 07728, United States
  • Austin Regional Clinic
    Austin, Texas 78731-3146, United States
  • Barwon Rheumatology Services
    Geelong, 3220, Australia
  • Southern Clinical Research
    Hobart, 7000, Australia
  • Liverpool Hospital
    Liverpool, 2170, Australia
  • Rheumatology Research Unit
    Maroochydore, 4558, Australia
  • Eastern Health - Box Hill Hospital
    Melbourne, 3128, Australia
  • Queen Elizabeth Hospital
    Woodville South, 5011, Australia
  • Eastern Regional Health Authority, St. Clare's Mercy Hospital
    St. John's, Newfoundland and Labrador A1C 5B8, Canada
  • The Waterside Clinic
    Barrie, Ontario L4M 6L2, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
    Quebec, G1V 3M7, Canada
  • Revmaclinic
    Brno, 61141, Czechia
  • MUDr. Rosypalova, s.r.o
    Ostrava, 70800, Czechia
  • Revmatologicka ambulance
    Praha 4, 14000, Czechia
  • Revmatologicky ustav
    Praha, 12850, Czechia
  • Medical Plus S.R.O.
    Uherske Hradiste, 68601, Czechia
  • PV-Medical S.R.O
    Zlin, 76001, Czechia
  • ISA GmbH
    Berlin, 10789, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • MVZ Rheuma
    Hamburg, 20095, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44649, Germany
  • Krankenhaus St. Josef
    Wuppertal, 42105, Germany
  • Orszagos Reumatologia es Fizioterapias Intezet
    Budapest, 1023, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, 1062, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Martinus Medicus Health Center
    Szombathely, 9700, Hungary
  • Seoul National University Bundang Hospital
    Bundang, 13620, Korea, Republic of
  • Hanyang University Hospital for rheumatic Diseases
    Seoul, 04763, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • SMG - SNU Boramae Medical Center
    Seoul, 7061, Korea, Republic of
  • Ajou University Hospital
    Suwon, 16499, Korea, Republic of
  • Hospital Selayang
    Batu Caves, 68100, Malaysia
  • Hospital Pulau Pinang
    Georgetown, 10990, Malaysia
  • Hospital Raja Permaisuri Bainun
    Ipoh, 30990, Malaysia
  • Hospital Melaka
    Melaka, 75400, Malaysia
  • Hospital Tuanku Jaafar
    Seremban, 70300, Malaysia
  • Nzoz Osteo-Medic
    Bialystok, 15-351, Poland
  • Szpital Uniwersytecki Nr 2 w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • NSZOZ Unica CR
    Dabrowka, 62-069, Poland
  • Centrum Kliniczno Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
    Elblag, 82-300, Poland
  • Etyka Osrodek Badan Klinicznych
    Olsztyn, 10-117, Poland
  • Centrum Medyczne Hetmańska
    Poznań, 60-218, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, 87-100, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
    Warszawa, 02-637, Poland
  • Centrum Medyczne WroMedica
    Wroclaw, 51-685, Poland
  • Nzoz Biogenes Sp. Z O. O.
    Wroclaw, 53-224, Poland
  • Chelyabinsk Regional Clinical Dermatovenerological Dispensary
    Chelyabinsk, 454092, Russian Federation
  • Medical and Sanitary Unit ''Severstal''
    Cherepovets, 162600, Russian Federation
  • Research Institute of Dermatovenerology, Immunology
    Ekaterinburg, 620076, Russian Federation
  • Krasnoyarsk State Medical University
    Krasnoyarsk, 660022, Russian Federation
  • Lipetsk Regional Dermatovenerological Dispensary
    Lipetsk, 398005, Russian Federation
  • Rostov Regional Clinical Dermatovenerological Dispensary
    Rostov, 344007, Russian Federation
  • Ryazan Regional Clinical Dermatovenerological Dispensary
    Ryazan, 390046, Russian Federation
  • Republican Clinical Hospital - G.G. Kuvatov
    Ufa, 450005, Russian Federation
  • Clinical Emergency Hospital n.a. N.V. Solovyev
    Yaroslavl, 150003, Russian Federation
  • Clinical Hospital #10
    Yaroslavl, 150023, Russian Federation
  • Hosp. Univ. A Coruña
    A Coruna, 15006, Spain
  • Hosp. Del Mar
    Barcelona, 08003, Spain
  • Hosp. Gral. Univ. Gregorio Marañon
    Madrid, 28007, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Regional Carlos Haya
    Málaga, 29009, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Infanta Luisa
    Sevilla, 41010, Spain
  • Hosp. Unv. de Valme
    Sevilla, 414014, Spain
  • Hosp. de Manises
    Valencia, 46940, Spain
  • Hualien Tzu Chi Hospital
    Hualien City, 970, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung, 81362, Taiwan
  • Chang Gung Memorial Hospital Kaohsiung Branch
    Kaohsiung, 833, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • National Cheng Kung University Medical Center
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Kung Memorial Hospital
    Taipei, 105, Taiwan
  • Chang-Gung Memorial Hospital, LinKou Branch
    Taoyuan, 333, Taiwan
  • Municipal health care institution Chernihiv Regional Hospital
    Chernihiv, Ukraine
  • Ivano-Frankivsk National Medical University, Ivano-Frankivsk City Clinical Hospital
    Ivano-Frankivsk, Ukraine
  • Communal Institution of Health Kharkiv City multifield hospital №18
    Kharkiv, 61029, Ukraine
  • Municipal Institution Regional hospital-center of emergency care and disasters medicine
    Kharkiv, Ukraine
  • Khmelnitckiy regional hospital
    Khmelnytsky, Ukraine
  • Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine'
    Kyiv, Ukraine
  • Kyiv Railway Station Clinical Hospital #2
    Kyiv, Ukraine
  • Danylo Halytsky Lviv National Medical University
    Lviv, Ukraine
  • Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
    Odessa, 65025, Ukraine
  • Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
    Ternopil, Ukraine
09

References and documents

Publications

  • Orbai AM, Coates LC, Deodhar A, Helliwell PS, Ritchlin CT, Leibowitz E, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Jiang Y, Liu Y, Han C. Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. Patient. 2022 Nov;15(6):657-668. doi: 10.1007/s40271-022-00588-6. Epub 2022 Jun 30. PubMed 35768650 ↗
  • Coates LC, Ritchlin CT, Gossec L, Helliwell PS, Rahman P, Kollmeier AP, Xu XL, Shawi M, Karyekar CS, Contre C, Noel W, Sheng S, Wang Y, Xu S, Mease PJ. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023 Feb 1;62(2):606-616. doi: 10.1093/rheumatology/keac375. PubMed 35766811 ↗
  • Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Schiopu E, Chakravarty SD, Kollmeier AP, Xu XL, Shawi M, Jiang Y, Sheng S, Wang Y, Xu S, Merola JF, McInnes IB, Deodhar A. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022 Mar;8(1):e002195. doi: 10.1136/rmdopen-2022-002195. PubMed 35296534 ↗
  • Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021 Jul 14;23(1):190. doi: 10.1186/s13075-021-02554-3. PubMed 34261541 ↗
  • Sweet K, Song Q, Loza MJ, McInnes IB, Ma K, Leander K, Lakshminarayanan V, Franks C, Cooper P, Siebert S. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open. 2021 May;7(2):e001679. doi: 10.1136/rmdopen-2021-001679. PubMed 34011674 ↗
  • Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. J Rheumatol. 2021 Dec;48(12):1815-1823. doi: 10.3899/jrheum.201532. Epub 2021 May 1. PubMed 33934076 ↗
  • McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Ritchlin CT, Rahman P, Mease PJ. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford). 2021 Nov 3;60(11):5337-5350. doi: 10.1093/rheumatology/keab285. PubMed 33822898 ↗
  • Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Erratum In: Lancet. 2020 Apr 4;395(10230):1114. doi: 10.1016/S0140-6736(20)30680-2. PubMed 32178765 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2019, 18 months.

Results were first posted in Oct 2020, 1 year 7 months after primary completion. A results delay was requested in Mar 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 18 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2017
First posted
May 22, 2017
StartActual
Aug 24, 2017
Primary completionActual
Mar 14, 2019
CompletionActual
Nov 18, 2019
Results delay requested
Mar 13, 2020
Results first posted
Oct 14, 2020
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03162796
Responsible party
Sponsor
First posted
May 22, 2017
Start date
Aug 24, 2017
Primary completion
Mar 14, 2019
Completion
Nov 18, 2019
Results posted
Oct 14, 2020
Last update
Feb 3, 2021

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion